東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

FindBook

Google Book

Amazon

博客來

Designing a Next-Generation Epstein-Barr Virus Vaccine.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Designing a Next-Generation Epstein-Barr Virus Vaccine./
作者:	Malhi, Harman.
面頁冊數:	1 online resource (112 pages)
附註:	Source: Dissertations Abstracts International, Volume: 84-07, Section: B.
Contained By:	Dissertations Abstracts International84-07B.
標題:	Immunology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29991941click for full text (PQDT)
ISBN:	9798368439419

Designing a Next-Generation Epstein-Barr Virus Vaccine.
Malhi, Harman.

Designing a Next-Generation Epstein-Barr Virus Vaccine. - 1 online resource (112 pages)

Source: Dissertations Abstracts International, Volume: 84-07, Section: B.

Thesis (Ph.D.)--University of Washington, 2022.

Includes bibliographical references

Epstein-Barr virus (EBV) is a cancer-associated pathogen responsible for 165,000 deaths per year. EBV is also the etiological agent of infectious mononucleosis and is associated with multiple sclerosis and rheumatoid arthritis. Thus, an EBV vaccine could alleviate significant morbidity and mortality. EBV is orally transmitted and has tropism for both epithelial cells and B cells. Therefore, a vaccine would need to prevent infection of both cell types in the oral cavity. I describe how the passive transfer of AMMO1, a dual-tropic neutralizing monoclonal antibody targeting the viral gH/gL glycoprotein complex, prevents experimental EBV infection in humanized mice and rhesus macaques, suggesting that gH/gL is an attractive vaccine candidate. Spurred by these findings, we produced and evaluated the immunogenicity of several nanoparticle immunogens displaying gH/gL with distinct valencies and geometries. After one or two immunizations, all nanoparticles elicited superior binding and neutralizing titers relative to monomeric gH/gL. Antibodies elicited by a computationally designed self-assembling nanoparticle that displays 60 copies of the gH/gL protein conferred protection against a lethal dose of EBV in a humanized mouse challenge model, whereas antibodies elicited by monomeric gH/gL did not. Taken together, these data motivate further development of nanoparticle vaccine candidates for EBV which target the gH/gL glycoprotein.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2023

Mode of access: World Wide Web

ISBN: 9798368439419Subjects--Topical Terms:

611031
Immunology.
Subjects--Index Terms:

Epstein-Barr virusIndex Terms--Genre/Form:

542853
Electronic books.

Designing a Next-Generation Epstein-Barr Virus Vaccine.
LDR:02749nmm a2200385K 4500 001 2365715
005 20231218204647.5
006 m o d
007 cr mn ---uuuuu
008 241011s2022 xx obm 000 0 eng d
020 $a 9798368439419
035 $a (MiAaPQ)AAI29991941
035 $a AAI29991941
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Malhi, Harman. $3 3706582
245 1 0 $a Designing a Next-Generation Epstein-Barr Virus Vaccine.
264 0 $c 2022
300 $a 1 online resource (112 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 84-07, Section: B.
500 $a Advisor: Mcguire, Andrew.
502 $a Thesis (Ph.D.)--University of Washington, 2022.
504 $a Includes bibliographical references
520 $a Epstein-Barr virus (EBV) is a cancer-associated pathogen responsible for 165,000 deaths per year. EBV is also the etiological agent of infectious mononucleosis and is associated with multiple sclerosis and rheumatoid arthritis. Thus, an EBV vaccine could alleviate significant morbidity and mortality. EBV is orally transmitted and has tropism for both epithelial cells and B cells. Therefore, a vaccine would need to prevent infection of both cell types in the oral cavity. I describe how the passive transfer of AMMO1, a dual-tropic neutralizing monoclonal antibody targeting the viral gH/gL glycoprotein complex, prevents experimental EBV infection in humanized mice and rhesus macaques, suggesting that gH/gL is an attractive vaccine candidate. Spurred by these findings, we produced and evaluated the immunogenicity of several nanoparticle immunogens displaying gH/gL with distinct valencies and geometries. After one or two immunizations, all nanoparticles elicited superior binding and neutralizing titers relative to monomeric gH/gL. Antibodies elicited by a computationally designed self-assembling nanoparticle that displays 60 copies of the gH/gL protein conferred protection against a lethal dose of EBV in a humanized mouse challenge model, whereas antibodies elicited by monomeric gH/gL did not. Taken together, these data motivate further development of nanoparticle vaccine candidates for EBV which target the gH/gL glycoprotein.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2023
538 $a Mode of access: World Wide Web
650 4 $a Immunology. $3 611031
650 4 $a Virology. $3 642304
650 4 $a Medicine. $3 641104
653 $a Epstein-Barr virus
653 $a Nanoparticle
653 $a Vaccine
653 $a Virology
655 7 $a Electronic books. $2 lcsh $3 542853
690 $a 0982
690 $a 0720
690 $a 0564
710 2 $a ProQuest Information and Learning Co. $3 783688
710 2 $a University of Washington. $b Molecular Medicine and Mechanisms of Disease. $3 3706583
773 0 $t Dissertations Abstracts International $g 84-07B.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29991941 $z click for full text (PQDT)